NetworkNewsWire Editorial
Coverage: By now, the potential for
cannabinoids like tetrahydrocannabinol (THC) and cannabidiol (CBD)
to reduce the symptoms and even help prevent the onset of diseases
such as Alzheimer’s has been fairly well-documented by a wide
variety of studies (http://nnw.fm/RRjS8). The global potential for
cannabis-based therapies has triggered a medical marijuana arms
race, as countries like Canada, Israel and many of those in Western
Europe seize the initiative and more boldly go where the U.S.
federal government has feared to allow private industry to tread.
Rising stars in the sector, such as phytocannabinoid combination
therapy developer India Globalization Capital, Inc. (NYSE
MKT: IGC) (IGC
Profile), are acutely aware of this
immense global potential and have begun to position themselves to
secure what will no doubt be hotly-contested market share.
Investors interested in medicinal marijuana and/or Alzheimer’s
treatments will find themselves looking at a global landscape of
key players that includes Medical Marijuana, Inc. (OTC:
MJNA), the first U.S. publicly traded cannabis company, as
well as Canadian pharmaceutical-grade marijuana producers
Aphria, Inc. (OTCQB: APHQF) (TSX: APH),
MYM Nutraceuticals, Inc. (OTCQB: MYMMF) (CNSX:
MYM) and Supreme Pharmaceuticals, Inc. (OTC:
SPRWF) (TSXV: FIRE).
As attitudes grow increasingly favorable to the medicinal
capabilities of cannabis, the companies that excel in this new
field are those focused on the development of therapies that
address global market concerns, such as Alzheimer’s. According to
the Alzheimer’s Association, Alzheimer’s disease and other
dementias will cost the U.S. roughly $259 billion in 2017 and, by
2050, could rise to as much as $1.1 trillion (http://nnw.fm/OzoX8).
Help may be on the way, though, as India
Globalization Capital, Inc. (IGC) is now on the verge
of bringing a potential blockbuster treatment for Alzheimer’s to
market as soon as early 2018 (http://nnw.fm/8pkAv). Through a license agreement with
the University of South Florida (http://nnw.fm/Ny7N0), IGC is the exclusive licensee of
the U.S. patent filing “THC as a Potential Therapeutic Agent for
Alzheimer’s Disease,” putting the company on track with a unique
advantage in the global Alzheimer’s drug market, which is currently
valued at roughly $3.6 billion (http://nnw.fm/b6AVl).
Novel in vitro data (http://nnw.fm/wvwX7) aggregated by IGC using
genetically engineered cell lines add substantial weight to the
existing argument about low doses of THC addressing the link
between amyloid beta peptide (Aβ plaque) buildup in the cerebral
cortex/hippocampus and Alzheimer’s (http://nnw.fm/lnxQ1). Given that the dominant
therapies for Alzheimer’s cannot stop or reverse disease
progression, the mounting evidence that THC and CBD can stop or
even reverse the symptoms of this disease (while providing
neuroprotective benefits) is huge (http://nnw.fm/f8RVr).
Today’s dominant Alzheimer’s therapies, such as Allergan’s (AGN)
Namenda, Daiichi Sankyo’s (DSNKY, DSKYF) Memary, Novartis’s (NVS)
Exelon and the drug Aricept developed by Pfizer (PFE) and Eisai
(ESALY, ESALF), may soon find themselves supplanted by disruptive
new technologies based on extremely old natural substances, like
cannabis, which have been in continuous human use for
centuries.
Notably, while IGC’s potential is of impressive significance,
the company’s market valuation of $10 million is a drop in a bucket
compared to other Alzheimer’s players such as Allergan (NYSE: AGN),
valued at $60+ billion; Novartis (NYSE: NVS) at $213 billion, and
Pfizer (NYSE: PFE) with a market cap of over $210 billion. While
IGC has considerable room to grow as investors become aware of its
true value, the company offers potentially the most substantial
product in the industry. If its aforementioned patent is approved,
IGC will own the key therapeutic pathway by which THC interacts
with the human body.
The new in vitro data from IGC extend earlier findings regarding
the company’s IGC-AD1 product (Hyalolex, http://nnw.fm/Xb0f4), which showed up to 50 percent
reduction in the production of the two key peptides that make up
the amyloid plaques found in abundance within the brains of
Alzheimer’s patients (http://nnw.fm/o5PGh). Moreover, because Alzheimer’s
starts several decades before symptoms begin to exhibit, a drug
like IGC-AD1, which has demonstrated an ability to decrease
production/aggregation of Aβ plaque without neurotoxic effects or
inebriation, could become a leading prophylactic treatment taken by
millions as a way to prevent Alzheimer’s.
Building on this potential, IGC is gearing up to commercialize a
non-inebriating liquid supplement version of the product for the
licensed medical dispensary market (http://nnw.fm/4RgWz), which has demonstrated an
ability to enhance mitochondrial function (a trigger for
Alzheimer’s pathophysiology) by as much as 60 percent in vitro
(http://nnw.fm/0kf0N). This readily
commercialized combination therapy could give IGC significant,
immediate ground game in this burgeoning retail space and help
support the company’s clinical work. This one-two punch approach,
with a food supplement in one hand and an FDA
prophylactic/therapeutic indication in the other, is as powerful as
it is solidly backed by exclusively-licensed IP.
Germany alone has nearly 83 million people, and the most common
cause behind the 1.6 million-plus dementia cases in that country is
Alzheimer’s (http://nnw.fm/Y1F5z). As such, the recent announcement
that IGC has entered into an MOU with leading Hamburg-based medical
cannabis information and services provider MediCann Handels GmbH
(http://nnw.fm/ssMn9) to import and distribute
IGC’s cannabinoid-based therapies to German pharmacies has been
music to savvy investors’ ears. This is a serious boon for IGC,
which marks the first step of many along the company’s path to
commercialization and is a real sweetheart of a deal, with MediCann
footing the bill for the logistics, as well as sales and
marketing.
Medical Marijuana (MJNA), with a current
estimated market valuation of $67 million, is also eyeing its
potential in the Alzheimer’s market, with its Real Scientific Hemp
Oil (“RSHO™”) products taking shape as leading CBD hemp oil
solutions in several international markets. In February 2017, MJNA
announced (http://nnw.fm/5B76p) that the Brazilian government
authorized a doctor's prescription for RSHO™ to treat a patient
with Alzheimer’s disease.
"Treatment solutions for neurological diseases like Alzheimer's
and Parkinson's are desperately needed because of the difficulty in
developing pharmaceuticals that can pass the blood-brain barrier, a
specialized system of cells that allow nutrients in the brain while
preventing harmful substances from passing through," MJNA CEO Dr.
Stuart Titus stated in the press release. "Cannabinoids like CBD,
however can pass through the blood-brain barrier and affect
cannabinoid/other receptors in the brain and an early stage study
has shown the potential benefit of cannabis and cannabinoid
therapies for Alzheimer's disease. This will lead us toward future
cannabinoid remedies and research to convince the medical community
of potential benefits."
MJNA currently has three products approved for importation into
Brazil, which are subsidized by the government as prescription
medications for chronic pain, epilepsy, and Parkinson’s
disease.
With mounting interest in the potential of cannabis-based
therapies, the demand for medicinal-grade cannabis production
continues to increase. Canadian medical cannabis provider
Aphria (APHQF) recently completed its initial
shipment of cannabis oil to Australian medical life science company
Medlab Clinical (http://nnw.fm/x0nFO). Aphira will produce and supply
high-yield cannabis extracts for Medlab’s upcoming,
first-of-its-kind globally, human trial of its cannabis-based
NanaBis™ in intractable pain among oncology patients. With product
formulation and permits for the agreement already approved by both
Health Canada and the Australian Therapeutic Goods Administration,
investors can see why eyes are increasingly turning overseas amid
the continued blossoming of the cannabis sector into a full-fledged
industry, with global horizons in the ballpark of $56 billion by
2025 for just the non-recreational segment (http://nnw.fm/6Futo).
In Australia, MYM Nutraceuticals (MYMMF) is
focused on acquiring Health Canada licenses to produce and sell
high-end organic medicinal cannabis supplements and topical
products. The company recently entered into a strategic partnership
with PUF Ventures, Inc. (CSE: PUF) (FRA: PU3) (OTC: PUFXF) for the
construction of a one million-square-foot greenhouse facility with
large-scale manufacturing, processing and office facilities for the
cultivation, production and manufacture of medical cannabis and
associated products. At full scale, the Northern Rivers Project
will have the capacity to produce 100,000 kilograms of high quality
cannabis per year, which would be worth between C$800 million and
C$1.1 billion based on current pricing metrics in the Australian
cannabis marketplace (http://nnw.fm/nPNV9).
Supreme Pharmaceuticals (SPRWF) is dedicated to
becoming a leading cultivator and supplier of cannabis in federally
legal and regulated global markets. SPRWF is primed for access to
global operators in the sector via its wholly owned 7ACRES
subsidiary, with sales already going swimmingly to other Canadian
players such as retail partner Aurora Cannabis (ACBFF) and
medicines developer Emerald Health Therapeutics (EMHTF). The
company even recently tacked on another 30,000 square feet at its
(now) 342,000-square-foot hybrid greenhouse facility in Ontario
(http://nnw.fm/SuWN0).
With nearly 44 million people suffering from Alzheimer’s or a
related dementia worldwide and an estimated total health care cost
of some $605 billion, this one vector could carry much of the
existing cannabis market, if a suitable THC/CBD-based treatment is
developed. Until many more U.S. states pass reform legislation or
the federal government reverses its stance on the drug, it seems
reasonable that market participants will continue to focus on
global opportunities. As a small-cap racing alongside large-cap
peers, IGC is geared up to capture its share of the medicinal
marijuana and Alzheimer’s disease treatment markets, propelled by
potential patent protection for its market-ready technology, and
in-vitro, in-vivo clinical data showing the efficacy of its
formulation.
For more information on India Globalization
Capital please visit: India
Globalization Capital, Inc. (IGC)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
MYM Nutraceuticals (CSE:MYM)
Historical Stock Chart
From Nov 2024 to Dec 2024
MYM Nutraceuticals (CSE:MYM)
Historical Stock Chart
From Dec 2023 to Dec 2024
